Review Of GSK's Avandia Trial Flawed, FDA Official Says
A U.S. Food and Drug Administration official on Wednesday blasted a Duke University research group's re-examination of a GlaxoSmithKline PLC trial for the former blockbuster diabetes treatment Avandia, charging that the...To view the full article, register now.
Already a subscriber? Click here to view full article